Author Archives: Julian Upton

Is There Life After Big Pharma?

Guest blog by Pharm Exec Europe’s Jacky Law. It’s hard to get precise figures of how many people have been taken off the payroll at pharma and biotech companies recently. According to staffing firm, Challender, Gray and Christmas, the combined industries shed 58,969 jobs in the first nine months of 2009, 15,000 more than the whole [...]
Posted in Corporate Responsibility, Deals, Europe, Global, Guest Blog | Tagged , , , , , | Leave a comment

Nothing is Rotten in the State of Denmark

Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent. Denmark is still on the fringes of some European Union policies. Notably, it has not yet embraced the euro as a currency, and it keeps its distance from the common defence policy. But in one respect, its pharmaceutical industry has just shown that it is well abreast [...]
Posted in Europe, Global, Guest Blog, Regulatory | Tagged , , , , , , , | Leave a comment

US and Europe At Risk from Substandard Medicines

Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Posted in Biotech, Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety | Tagged , , , , , , , , , , , | Leave a comment

Europe: Of Apes and Ombudsmen

Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent. This column has frequently drawn attention to the complexities of getting anything done in Europe. A brilliant researcher can explore visionary horizons, an ambitious entrepreneur can offer a package of goods or services of inestimable value, but the degree of control and regulation becomes more intense [...]
Posted in Europe, Global, Regulatory | Tagged , , , , , | Leave a comment

Will Europe Stay Coy on Information to Patients?

Guest blog by Reflector, Pharm Exec Europe’s Brussels correspondent. American drug firms have been pushing for it for years, and so — in an entirely different direction — has the European Parliament. Patient groups are divided over whether it’s needed. The European Commission (EC) says it’s definitely time for action. But EU member states — and [...]
Posted in Strategy | Leave a comment